Cancer prevalence estimates in europeat the beginning of 2000

G. Gatta, S. Mallone, J. M. van der Zwan, A. Trama, S. Siesling, R. Capocaccia

Research output: Contribution to journalArticle

Abstract

Background: Complete cancer prevalence data in Europe have never been updated after the first estimates provided by the EUROPREVAL project and referred to the year 1993. This paper provides prevalence estimates for 16 majorcancers in Europe at the beginning of the year 2003.Patients and methods: We estimated complete prevalence by the completeness index method. We usedinformation on cancer patients diagnosed in 1978-2002 with vital status information available up to 31December 2003, from 76 European cancer registries.Results: About 11.6 millions of Europeans with a history of one of the major considered cancers were alive on1 January 2003. For breast and prostate cancers, about 1 out of 73 women and 1 out of 160 men were living with aprevious diagnosis of breast and prostate cancers, respectively. The demographic variations alone will increase thenumber of prevalent cases to nearly 13 millions in 2010.Conclusions: Several factors (early detection, population aging and better treatment) contribute to increase cancerprevalence and push for the need of a continuous monitoring of prevalence indicators to properly plan needs, resourceallocation to cancer and for improving health care programs for cancer survivors. Cancer prevalence should beincluded within the EU official health statistics.

Original languageEnglish
Pages (from-to)1660-1666
Number of pages7
JournalAnnals of Oncology
Volume24
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Neoplasms
Prostatic Neoplasms
Breast Neoplasms
Survivors
Registries
Demography
Delivery of Health Care
Health
Population
Therapeutics

Keywords

  • Aging
  • Cancer
  • Cancer registry
  • Europe
  • Prevalence

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Gatta, G., Mallone, S., van der Zwan, J. M., Trama, A., Siesling, S., & Capocaccia, R. (2013). Cancer prevalence estimates in europeat the beginning of 2000. Annals of Oncology, 24(6), 1660-1666. https://doi.org/10.1093/annonc/mdt030

Cancer prevalence estimates in europeat the beginning of 2000. / Gatta, G.; Mallone, S.; van der Zwan, J. M.; Trama, A.; Siesling, S.; Capocaccia, R.

In: Annals of Oncology, Vol. 24, No. 6, 06.2013, p. 1660-1666.

Research output: Contribution to journalArticle

Gatta, G, Mallone, S, van der Zwan, JM, Trama, A, Siesling, S & Capocaccia, R 2013, 'Cancer prevalence estimates in europeat the beginning of 2000', Annals of Oncology, vol. 24, no. 6, pp. 1660-1666. https://doi.org/10.1093/annonc/mdt030
Gatta, G. ; Mallone, S. ; van der Zwan, J. M. ; Trama, A. ; Siesling, S. ; Capocaccia, R. / Cancer prevalence estimates in europeat the beginning of 2000. In: Annals of Oncology. 2013 ; Vol. 24, No. 6. pp. 1660-1666.
@article{3d17943055804a469e8d3244267fd1e9,
title = "Cancer prevalence estimates in europeat the beginning of 2000",
abstract = "Background: Complete cancer prevalence data in Europe have never been updated after the first estimates provided by the EUROPREVAL project and referred to the year 1993. This paper provides prevalence estimates for 16 majorcancers in Europe at the beginning of the year 2003.Patients and methods: We estimated complete prevalence by the completeness index method. We usedinformation on cancer patients diagnosed in 1978-2002 with vital status information available up to 31December 2003, from 76 European cancer registries.Results: About 11.6 millions of Europeans with a history of one of the major considered cancers were alive on1 January 2003. For breast and prostate cancers, about 1 out of 73 women and 1 out of 160 men were living with aprevious diagnosis of breast and prostate cancers, respectively. The demographic variations alone will increase thenumber of prevalent cases to nearly 13 millions in 2010.Conclusions: Several factors (early detection, population aging and better treatment) contribute to increase cancerprevalence and push for the need of a continuous monitoring of prevalence indicators to properly plan needs, resourceallocation to cancer and for improving health care programs for cancer survivors. Cancer prevalence should beincluded within the EU official health statistics.",
keywords = "Aging, Cancer, Cancer registry, Europe, Prevalence",
author = "G. Gatta and S. Mallone and {van der Zwan}, {J. M.} and A. Trama and S. Siesling and R. Capocaccia",
year = "2013",
month = "6",
doi = "10.1093/annonc/mdt030",
language = "English",
volume = "24",
pages = "1660--1666",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Cancer prevalence estimates in europeat the beginning of 2000

AU - Gatta, G.

AU - Mallone, S.

AU - van der Zwan, J. M.

AU - Trama, A.

AU - Siesling, S.

AU - Capocaccia, R.

PY - 2013/6

Y1 - 2013/6

N2 - Background: Complete cancer prevalence data in Europe have never been updated after the first estimates provided by the EUROPREVAL project and referred to the year 1993. This paper provides prevalence estimates for 16 majorcancers in Europe at the beginning of the year 2003.Patients and methods: We estimated complete prevalence by the completeness index method. We usedinformation on cancer patients diagnosed in 1978-2002 with vital status information available up to 31December 2003, from 76 European cancer registries.Results: About 11.6 millions of Europeans with a history of one of the major considered cancers were alive on1 January 2003. For breast and prostate cancers, about 1 out of 73 women and 1 out of 160 men were living with aprevious diagnosis of breast and prostate cancers, respectively. The demographic variations alone will increase thenumber of prevalent cases to nearly 13 millions in 2010.Conclusions: Several factors (early detection, population aging and better treatment) contribute to increase cancerprevalence and push for the need of a continuous monitoring of prevalence indicators to properly plan needs, resourceallocation to cancer and for improving health care programs for cancer survivors. Cancer prevalence should beincluded within the EU official health statistics.

AB - Background: Complete cancer prevalence data in Europe have never been updated after the first estimates provided by the EUROPREVAL project and referred to the year 1993. This paper provides prevalence estimates for 16 majorcancers in Europe at the beginning of the year 2003.Patients and methods: We estimated complete prevalence by the completeness index method. We usedinformation on cancer patients diagnosed in 1978-2002 with vital status information available up to 31December 2003, from 76 European cancer registries.Results: About 11.6 millions of Europeans with a history of one of the major considered cancers were alive on1 January 2003. For breast and prostate cancers, about 1 out of 73 women and 1 out of 160 men were living with aprevious diagnosis of breast and prostate cancers, respectively. The demographic variations alone will increase thenumber of prevalent cases to nearly 13 millions in 2010.Conclusions: Several factors (early detection, population aging and better treatment) contribute to increase cancerprevalence and push for the need of a continuous monitoring of prevalence indicators to properly plan needs, resourceallocation to cancer and for improving health care programs for cancer survivors. Cancer prevalence should beincluded within the EU official health statistics.

KW - Aging

KW - Cancer

KW - Cancer registry

KW - Europe

KW - Prevalence

UR - http://www.scopus.com/inward/record.url?scp=84878436169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878436169&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdt030

DO - 10.1093/annonc/mdt030

M3 - Article

C2 - 23553062

AN - SCOPUS:84878436169

VL - 24

SP - 1660

EP - 1666

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -